168
Participants
Start Date
May 19, 2022
Primary Completion Date
September 18, 2023
Study Completion Date
October 16, 2023
XEN1101 10 mg
XEN1101 oral capsule
XEN1101 20 mg
XEN1101 oral capsule
Placebo
Placebo capsule
Manhattan Behavioral Medicine, PLLC, New York
Neurobehavioral Research, Inc. (NBR), Cedarhurst
Richard M Weisler and Association, Raleigh
i-Research, Atlanta, Decatur
Psych Atlanta, PC, Marietta
iResearch, Savannah
Meridian International Research, Miami
Global Medical Institutes (GMI), Miami
CCM Clinical Reseach Group, LLC, Miami
Revive Research Institute, Inc., Elgin
AIM Trials, Plano
FutureSearch Trials of Dallas, LP, Dallas
Altea Research, Las Vegas
California Neuropsychopharmacology Clinical Research Institute, Pico Rivera
Artemis Institute for Clinical Research, San Diego
Artemis Institute for Clinical Research, Riverside
Advanced Research Center, Anaheim
Sunwise Clinical Research, LLC, Lafayette
Hassman Research Institute, Marlton
Bio Behavioral Health, Toms River
Xenon Pharmaceuticals Inc.
INDUSTRY